PMID- 24571258
OWN - NLM
STAT- MEDLINE
DCOM- 20150402
LR  - 20211021
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 18
IP  - 3
DP  - 2014 Mar
TI  - Lactoferrin gene knockdown leads to similar effects to iron chelation in human 
      adipocytes.
PG  - 391-5
LID - 10.1111/jcmm.12234 [doi]
AB  - In human and mice adipose tissue, lactoferrin (LTF) has been found to be 
      associated with increased adipogenesis and decreased inflammatory markers. Here, 
      we aimed to investigate the effects of LTF knockdown (KD) in human adipocyte 
      differentiation. In addition, the effects of exogenous LTF administration and 
      iron chelation [using deferoxamine (DFO, 10 muM)] were tested. In both 
      subcutaneous and visceral pre-adipocytes, LTF KD led to decrease significantly 
      adipogenic, lipogenic and insulin signalling-related gene expression and a 
      significant increase in the gene expression of inflammatory mediators. Human 
      lactoferrin (hLf, 1 muM) administration led to recover adipocyte differentiation 
      in LTF KD pre-adipocytes. Interestingly, iron chelation triggered similar effects 
      to LTF KD, decreasing significantly adipogenic gene expressions. Of note, DFO (10 
      muM) and hLf (1 and 10 muM) co-administration led to a dose-dependent recovery of 
      adipocyte differentiation. These new data reveal that endogenous LTF biosynthesis 
      during human adipocyte differentiation is essential to achieve this process, 
      possibly, modulating adipocyte iron homoeostasis. hLf administration might be a 
      useful therapeutic target in obesity-associated adipose tissue dysfunction.
CI  - (c) 2014 The Authors. Journal of Cellular and Molecular Medicine published by John 
      Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
FAU - Moreno-Navarrete, Jose Maria
AU  - Moreno-Navarrete JM
AD  - Service of Diabetes, Endocrinology and Nutrition, Institut d'Investigacio 
      Biomedica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud 
      Carlos III (ISCIII), Girona, Spain.
FAU - Ortega, Francisco
AU  - Ortega F
FAU - Moreno, Maria
AU  - Moreno M
FAU - Serrano, Marta
AU  - Serrano M
FAU - Ricart, Wifredo
AU  - Ricart W
FAU - Fernandez-Real, Jose Manuel
AU  - Fernandez-Real JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140226
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Biomarkers)
RN  - 0 (Iron Chelating Agents)
RN  - E1UOL152H7 (Iron)
RN  - EC 3.4.21.- (Lactoferrin)
RN  - J06Y7MXW4D (Deferoxamine)
SB  - IM
MH  - Adipocytes/*metabolism
MH  - Adipogenesis/drug effects
MH  - Biomarkers/metabolism
MH  - Deferoxamine/pharmacology
MH  - *Gene Knockdown Techniques
MH  - Humans
MH  - Inflammation/pathology
MH  - Iron/*metabolism
MH  - Iron Chelating Agents/*pharmacology
MH  - Lactoferrin/*genetics/pharmacology
PMC - PMC3955146
OTO - NOTNLM
OT  - adipocytes
OT  - adipogenesis
OT  - iron metabolism
OT  - lactoferrin
EDAT- 2014/02/28 06:00
MHDA- 2015/04/04 06:00
PMCR- 2014/03/01
CRDT- 2014/02/28 06:00
PHST- 2013/10/17 00:00 [received]
PHST- 2013/12/18 00:00 [accepted]
PHST- 2014/02/28 06:00 [entrez]
PHST- 2014/02/28 06:00 [pubmed]
PHST- 2015/04/04 06:00 [medline]
PHST- 2014/03/01 00:00 [pmc-release]
AID - 10.1111/jcmm.12234 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2014 Mar;18(3):391-5. doi: 10.1111/jcmm.12234. Epub 2014 Feb 26.